CoChat
Sign Up
Cited by 141Pregnancy and preeclampsia studiesProtease and Inhibitor MechanismsNeurological Complications and Syndromes

Role of Gelatinases MMP-2 and MMP-9 in Healthy and Complicated Pregnancy and Their Future Potential as Preeclampsia Biomarkers

Open access
Nikolov, Asparuh, Popovski, Nikola·2021·Diagnostics
DOI 10.3390/diagnostics11030480PMC PMC8001076
Open this paper in CoChat — free accountOpen PDF

Abstract

Gelatinases (matrix metalloproteinase-2 and -9) are enzymes from the matrix metalloproteinases (MMPs) family, which are associated with collagen degradation. MMP-2 is capable of cleaving gelatine, types I and IV collagens, while MMP-9 is incapable of direct proteolysis of collagen I and digests collagen type IV. MMP-2 and -9 are both important regulators of vascular and uterine remodeling in a healthy pregnancy. Alterations in the collagen structure of the uterus and spiral arteries are observed in women with hypertensive disorders of pregnancy. Dysregulation of MMP-2 and MMP-9 has been implicated in abnormal vasodilation, placentation, and uterine expansion in preeclampsia. Early preeclampsia detection is paramount for risk stratification and prevention of further complications. Understanding the role of MMP-2 and-9 in uteroplacental and vascular remodeling could help design new approaches for prediction and management of preeclampsia. This review presents a general survey of MMP-2 and MMP-9 faulty regulation and impaired collagen types I and IV turnover in complicated pregnancies. Their potential role as circulating markers for diagnosis, prognosis, and monitoring of preeclampsia development is discussed as well.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/diagnostics11030480

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 84 · Cited by 141

Research works printed but not linked: 82

  1. [1]Henriksen K. Karsdal M.A. Type I Collagen Biochemistry of Collagens, Laminins and Elastin Structure, Function and Biomarkers 1st ed. Karsdal M.A. Academic Press Cambridge, MA, USA 2016 Chapter 1 1 11
  2. [2]Fleischmajer R. Macdonald E.D. Perlish J.S. Burgeson R.E. Fisher L.W. Dermal collagen fibrils are hybrids of type I and type III collagen molecules J. Struct. Biol. 1990 105 162 169 10.1016/1047-8477(90)90110-X 2100147 · DOI
  3. [3]Niyibizi C. Eyre D.R. Bone type V collagen: Chain composition and location of a trypsin cleavage site Connect. Tissue Res. 1989 20 247 250 10.3109/03008208909023894 2612158 · DOI
  4. [4]Gelse K. Collagens—Structure, function, and biosynthesis Adv. Drug Deliv. Rev. 2003 55 1531 1546 10.1016/j.addr.2003.08.002 14623400 · DOI
  5. [5]Sand J.M.B. Genovese F. Gudmann N.S. Karsdal M.A. Type IV collagen Biochemistry of Collagens, Laminins and Elastin 2nd ed. Karsdal M.A. Elsevier Amsterdam, The Netherlands 2019 Chapter 4 37 49
  6. [6]Mansell J.P. Bailey A.J. Collagen Metabolism Encyclopedia of Endocrine Diseases Martini L. Elsevier Amsterdam, The Netherlands 2004 520 529
  7. [7]Hudson B.G. Tryggvason K. Sundaramoorthy M. Neilson E.G. Alport’s syndrome, Goodpasture’s syndrome, and type IV collagen N. Engl. J. Med. 2003 348 2543 2556 10.1056/NEJMra022296 12815141 · DOI
  8. [8]Tryggvason L. Patrakka J. Alport’s Disease and Thin Basement Membrane Nephropathy Genetic Diseases of the Kidney Lifton R.P. Somlo S. Giebisch G.H. Elsevier Amsterdam, The Netherlands 2009 Chapter 4 77 96
  9. [9]Visse R. Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure function and biochemistry Circ. Res. 2003 92 827 839 10.1161/01.RES.0000070112.80711.3D 12730128 · DOI · Paper page
  10. [10]Somerville R. Oblander S. Apte S. Matrix metalloproteinases: Old dogs with new tricks Genome Biol. 2003 4 216 10.1186/gb-2003-4-6-216 12801404 PMC193609 · DOI
  11. [11]Stoneman V.E.A. Bennett M.R. Role of apoptosis in atherosclerosis and its therapeutic implications Clin. Sci. 2004 107 343 354 10.1042/CS20040086 15230690 · DOI
  12. [12]Galis Z.S. Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly Circ. Res. 2002 90 251 262 10.1161/res.90.3.251 11861412 · DOI
  13. [13]Aimes R.T. Quigley J.P. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments J. Biol. Chem. 1995 270 5872 5876 10.1074/jbc.270.11.5872 7890717 · DOI
  14. [14]Patterson M.L. Atkinson S.J. Knäuper V. Murphy G. Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain FEBS Lett. 2001 503 158 162 10.1016/S0014-5793(01)02723-5 11513874 · DOI
  15. [15]Nagase H. Visse R. Murphy G. Structure and function of matrix metalloproteinases and TIMPs—Review Cardiovasc. Res. 2006 69 562 573 10.1016/j.cardiores.2005.12.002 16405877 · DOI
  16. [16]Klein T. Bischoff R. Physiology and pathophysiology of matrix metalloproteases—Review Amino Acids 2011 41 271 290 10.1007/s00726-010-0689-x 20640864 PMC3102199 · DOI
  17. [17]Templeton N.S. Stetler-Stevenson W.G. Identification of a basal promoter for the human Mr 72,000 type IV collagenase gene and enhanced expression in a highly metastatic cell line Cancer Res. 1991 51 6190 6193 1657382
  18. [18]Murphy G. Nguyen Q. Cockett M.I. Atkinson S.J. Allan J.A. Knight C.G. Willenbrock F. Docherty A.J. Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant J. Biol. Chem. 1994 269 6632 6636 10.1016/S0021-9258(17)37419-7 8120015 · DOI
  19. [19]Chakrabarti S. Patel K.D. Matrix metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology Exp. Lung Res. 2005 31 599 621 10.1080/019021490944232 16019990 · DOI
  20. [20]Nagase H. Cell surface activation of progelatinaseA (proMMP-2) and cell migration Cell Res. 1998 8 179 186 10.1038/cr.1998.18 9791731 · DOI
  21. [21]Sopata I. Dancewicz A.M. Presence of a gelatin-specific proteinase and its latent form in human leucocytes Biochim. Biophys. Acta 1974 370 510 523 10.1016/0005-2744(74)90112-0 4216367 · DOI
  22. [22]Mattu T.S. Royle L. Langridge J. Wormald M.R. Van den Steen P.E. Van Damme J. Opdenakker G. Harvey D.J. Dwek R.A. Rudd P.M. O-glycan analysis of natural human neutrophil gelatinase B using a combination of normal phase-HPLC and online tandem mass spectrometry: Implications for the domain organization of the enzyme Biochemistry 2000 39 15695 15704 10.1021/bi001367j 11123894 · DOI
  23. [23]Ogata Y. Enghild J.J. Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9 J. Biol. Chem. 1992 267 3581 3584 10.1016/S0021-9258(19)50563-4 1371271 · DOI
  24. [24]Maeda H. Okamoto T. Akaike T. Human matrix metalloprotease activation by insults of bacterial infection involving proteases and free radicals Biol. Chem. 1998 379 193 200 10.1515/bchm.1998.379.2.193 9524071 · DOI
  25. [26]Ezhilarasan R. Jadhav U. Mohanam I. Rao J.S. Gujrati M. Mohanam S. The hemopexin domain of MMP-9 inhibits angiogenesis and retards the growth of intracranial glioblastoma xenograft in nude mice Int. J. Cancer. 2009 124 306 315 10.1002/ijc.23951 18942717 PMC2814063 · DOI
  26. [27]Lemjabbar H. Gosset P. Lamblin C. Tillie I. Hartmann D. Wallaert B. Tonnel A.B. Lafuma C. Contribution of 92 kDa gelatinase/type IV collagenase in bronchial inflammation during status asthmaticus Am. J. Respir. Crit. Care Med. 1999 159 1298 1307 10.1164/ajrccm.159.4.9708080 10194181 · DOI
  27. [28]Van den Steen P.E. Dubois B. Nelissen I. Rudd P.M. Dwek R.A. Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9) Crit. Rev. Biochem. Mol. Biol. 2002 37 375 536 10.1080/10409230290771546 12540195 · DOI
  28. [29]Lei H. Vadillo-Ortega F. Paavola L.G. Strauss J.F. 92–kDa gelatinase (matrix metalloproteinase-9) is induced in rat amnion immediately prior to parturition Biol. Reprod. 1995 53 339 344 10.1095/biolreprod53.2.339 7492685 · DOI
  29. [30]Vadillo-Ortega F. Hernandez A. Gonzalez-Avila G. Bermejo L. Iwata K. Strauss J.F. Increased matrix metalloproteinase activity and reduced tissue inhibitor of metalloproteinases-1 levels in amniotic fluids from pregnancies complicated by premature rupture of membranes Am. J. Obstet. Am. J. Obstet. Gynecol. 1996 174 1371 1376 10.1016/S0002-9378(96)70687-7 8623872 · DOI
  30. [31]Vadillo-Ortega F. Gonzalez-Avila G. Furth E.E. Lei H. Muschel R.J. Stetler-Stevenson W.G. Strauss J.F. 92-kd type IV collagenase (matrix metalloproteinase-9) activity in human amniochorion increases with labor Am. J. Pathol. 1995 146 148 156 7856724 PMC1870762
  31. [32]Crocker S.J. Pagenstecher A. Campbell I.L. The TIMPs tango with MMPs and more in the central nervous system J. Neurosci. Res. 2004 75 1 11 10.1002/jnr.10836 14689443 · DOI
  32. [33]Devarajan P. Johnston J.J. Ginsberg S.S. Van Wart H.E. Berliner N. Structure and expression of neutrophil gelatinase cDNA. Identity with type IV collagenase from HT1080 cells J. Biol. Chem. 1992 267 25228 25232 10.1016/S0021-9258(19)74029-0 1460022 · DOI
  33. [34]Opdenakker G. Masure S. Grillet B. Van Damme J. Cytokinemediated regulation of human leukocyte gelatinases and role in arthritis Lymphokine Cytokine Res. 1991 10 317 324 1932376
  34. [35]Baruch R.R. Melinscak H. Lo J. Liu Y. Yeung O. Hurta R.A. Altered matrix metalloproteinase expression associated with oncogene-mediated cellular transformation and metastasis formation Cell Biol. Int. 2001 25 411 420 10.1006/cbir.2000.0647 11401328 · DOI
  35. [36]Kjeldsen L. Johnsen A.H. Sengelov H. Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase J. Biol. Chem. 1993 268 10425 10432 10.1016/S0021-9258(18)82217-7 7683678 · DOI
  36. [37]Pereira R.D. De Long N.E. Wang R.C. Yazdi F.T. Holloway A.C. Raha S. Angiogenesis in the placenta: The role of reactive oxygen species signaling BioMed Res. Int. 2015 2015 814543 10.1155/2015/814543 25705690 PMC4325211 · DOI
  37. [38]Burton G.J. Woods A.W. Jauniaux E. Kingdom J.C. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy Placenta 2009 30 473 482 10.1016/j.placenta.2009.02.009 19375795 PMC2697319 · DOI
  38. [39]Espino Y. Sosa S. Flores-Pliego A. Espejel-Nuñez A. Medina-Bastidas D. Vadillo-Ortega F. Zaga-Clavellina V. Estrada-Gutierrez G. New Insights into the Role of Matrix Metalloproteinases in Preeclampsia Int. J. Mol. Sci. 2017 18 1448 10.3390/ijms18071448 PMC5535939 28726716 · DOI
  39. [40]Pollheimer J. Fock V. Knöfler M. Review: The ADAM metalloproteinases—Novel regulators of trophoblast invasion? Placenta 2014 35 S57 S63 10.1016/j.placenta.2013.10.012 24231445 · DOI
  40. [41]Carter A.M. Enders A.C. Pijnenborg R. The role of invasive trophoblast in implantation and placentation of primates Philos. Trans. R. Soc. Lond. B Biol. Sci. 2015 370 20140070 10.1098/rstb.2014.0070 25602074 PMC4305171 · DOI
  41. [42]Zhu J.Y. Pang Z.J. Yu Y.H. Regulation of trophoblast invasion: The role of matrix metalloproteinases Rev. Obstet. Gynecol. 2012 5 e137 e143 23483768 PMC3594863
  42. [43]Pulkkinen M. Lehto M. Jalkanen M. Näntö-Salonen K. Collagen types and fibronectin in the uterine muscle of normal and hypertensive pregnant patients Am. J. Obstet. Gynecol. 1984 149 711 717 10.1016/0002-9378(84)90108-X 6380293 · DOI
  43. [44]Sahay A.S. Sundrani D.P. Joshi S.R. Regional changes of placental vascularization in preeclampsia: A review IUBMB Life 2015 67 619 625 10.1002/iub.1407 26269153 · DOI
  44. [45]Wallis R.M. Hillier K. Regulation of collagen dissolution in the human cervix by oestradiol-17 beta and progesterone J. Reprod. Fertil. 1981 62 55 61 10.1530/jrf.0.0620055 7230136 · DOI
  45. [46]Sato T. Ito A. Mori Y. Yamashita K. Hayakawa T. Nagase H. Hormonal regulation of collagenolysis in uterine cervical fibroblasts. Modulation of synthesis of procollagenase, prostromelysin and tissue inhibitor of metalloproteinases (TIMP) by progesterone and oestradiol-17 beta Biochem. J. 1991 275 645 650 10.1042/bj2750645 1645518 PMC1150103 · DOI
  46. [47]Uldbjerg N. Forman A. Petersen L. Biochemical changes of the uterus and cervix during pregnancy Medicine of the Fetus and Mother Reece E.A. Hobbins J.C. Mahoney M.J. Petrie R.H. JB Lippincott Co. Philadelphia, PA, USA 1992 849 868
  47. [48]Chen J. Khalil R.A. MMP in Normal pregnancy and preeclampsia Prog. Mol. Biol. Transl. Sci. 2017 148 87 165 10.1016/bs.pmbts.2017.04.001 28662830 PMC5548443 · DOI
  48. [49]Montagnana M. Lippi G. Albiero A. Scevarolli S. Salvagno G.L. Franchi M. Guidi G.C. Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy J. Clin. Lab. Anal. 2009 23 88 92 10.1002/jcla.20295 19288452 PMC6649012 · DOI
  49. [50]Eleuterio N.M. Palei A.C. Rangel Machado J.S. Tanus-Santos J.E. Cavalli R.C. Sandrim V.C. Positive correlations between circulating adiponectin and MMP2 in preeclampsia pregnant Pregnancy Hypertens. 2015 5 205 208 10.1016/j.preghy.2015.03.001 25943646 · DOI
  50. [51]Khalil R.A. Granger J.P. Vascular mechanisms of increased arterial pressure in preeclampsia: Lessons from animal models Am. J. Phys. Regul. Integr. Comp. Phys. 2002 283 R29 R45 10.1152/ajpregu.00762.2001 12069928 · DOI
  51. [52]Gilbert J.S. Babcock S.A. Granger J.P. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression Hypertension 2007 50 1142 1147 10.1161/HYPERTENSIONAHA.107.096594 17923588 · DOI
  52. [53]Alexander B.T. Kassab S.E. Miller M.T. Abram S.R. Reckelhoff J.F. Bennett W.A. Granger J.P. Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide Hypertension 2001 37 1191 1195 10.1161/01.HYP.37.4.1191 11304523 · DOI
  53. [54]Eiland E. Nzerue C. Faulkner M. Preeclampsia J. Pregnancy 2012 2012 1 7 10.1155/2012/586578 PMC3403177 22848831 · DOI
  54. [55]Palei A.C. Granger J.P. Tanus-Santos J.E. Matrix metalloproteinases as drug targets in preeclampsia Curr. Drug Targets 2013 14 325 334 10.2174/1389450111314030004 23316964 PMC3675769 · DOI
  55. [56]Lin C. He H. Cui N. Ren Z. Zhu M. Khalil R.A. Decreased uterine vascularization and uterine arterial expansive remodeling with reduced matrix metalloproteinase-2 and -9 in hypertensive pregnancy Am. J. Physiol. Heart Circ. Physiol. 2020 318 H165 H180 10.1152/ajpheart.00602.2019 31834839 PMC6985805 · DOI
  56. [57]Lim K.H. Zhou Y. Janatpour M. McMaster M. Bass K. Chun S.H. Fisher S.J. Human cytotrophoblast differentiation/invasion is abnormal in pre-eclampsia Am. J. Pathol. 1997 151 1809 1818 9403732 PMC1858365
  57. [58]Goldman-Wohl D.S. Yagel S. Examination of distinct fetal and maternal molecular pathways suggests a mechanism for the development of preeclampsia J. Reprod. Immunol. 2007 76 54 60 10.1016/j.jri.2007.03.012 17482678 · DOI
  58. [59]Goldman-Wohl D. Yagel S. Regulation of trophoblast invasion: From normal implantation to pre-eclampsia Mol. Cell. Endocrinol. 2002 187 233 238 10.1016/S0303-7207(01)00687-6 11988332 · DOI
  59. [60]Karthikeyan V.J. Lane A.D. Beevers D.G. Lip G.Y.H. Blann A.D. Matrix metalloproteinases and their tissue inhibitors in hypertension-related pregnancy complications J. Hum. Hypertens. 2012 27 72 78 10.1038/jhh.2012.8 22418748 · DOI
  60. [61]Wang Q. Wang Z. Yao W. Wu X. Huang J. Huang L. Sun Y. Anthropometric Indices Predict the Development of Hypertension in Normotensive and Pre-Hypertensive Middle-Aged Women in Tianjin, China: A Prospective Cohort Study Med. Sci. Monit. 2018 24 CLR1871 CLR1879 10.12659/MSM.908257 PMC5892460 29601569 · DOI
  61. [62]Shimonovitz S. Hurwitz A. Dushnik M. Anteby E. Geva-Eldar T. Yagel S. Developmental regulation of the expression of 72 and 92 kd type IV collagenases in human trophoblasts: A possible mechanism for control of trophoblast invasion Am. J. Obstet. Gynecol. 1994 171 832 838 10.1016/0002-9378(94)90107-4 7522400 · DOI
  62. [63]Merchant S.J. Narumiya H. Zhang Y. Guilbert L.J. Davidge S.T. The effects of preeclampsia and oxygen environment on endothelial release of matrix metalloproteinase Hypertens. Pregnancy 2004 23 47 60 10.1081/PRG-120028281 15117600 · DOI
  63. [64]Su M.T. Tsai P.Y. Tsai H.L. Chen Y.C. Kuo P.L. miR-346 and miR-582-3p-regulated EG-VEGF expression and trophoblast invasion via matrix metalloproteinases 2 and 9 Biofactors 2017 43 210 219 10.1002/biof.1325 27619846 · DOI
  64. [65]Isaka K. Usuda S. Ito H. Sagawa Y. Nakamura H. Nishi H. Suzuki Y. Li Y.F. Takayama M. Expression and activity of matrix metalloproteinase 2 and 9 in human trophoblasts Placenta 2003 24 53 64 10.1053/plac.2002.0867 12495660 · DOI
  65. [66]Li W. Mata K.M. Mazzuca M.Q. Khalil R.A. Altered matrix metalloproteinase-2 and -9 expression/activity links placental ischemia and anti-angiogenic sFlt-1 to uteroplacental and vascular remodeling and collagen deposition in hypertensive pregnancy Biochem. Pharmacol. 2014 89 370 385 10.1016/j.bcp.2014.03.017 24704473 PMC4034157 · DOI
  66. [67]Ren Z. Cui N. Zhu M. Khalil R.A. Placental growth factor reverses decreased vascular and uteroplacental MMP-2 and MMP-9 and increased MMP-1 and MMP-7 and collagen types I and IV in hypertensive pregnancy Am. J. Physiol. Heart Circ. Physiol. 2018 315 H33 H47 10.1152/ajpheart.00045.2018 29569955 PMC6087780 · DOI
  67. [68]Hao S. You J. Lin C. Zhao H. Huang Y. Zheng L. Tian L. Maric I. Liu X. Li T. Changes in pregnancy-related serum biomarkers early in gestation are associated with later development of preeclampsia PLoS ONE 2020 15 e0230000 10.1371/journal.pone.0230000 32126118 PMC7053753 · DOI
  68. [69]Chen J. Ren Z. Zhu M. Khalil R.A. Decreased homodimerization and increased TIMP-1 complexation of uteroplacental and uterine arterial matrix metalloproteinase-9 during hypertension-in-pregnancy Biochem. Pharmacol. 2017 138 81 95 10.1016/j.bcp.2017.05.005 28506758 PMC5516730 · DOI
  69. [70]Dias-Junior C.A. Chen J. Cui N. Angiogenic imbalance and diminished matrix metalloproteinase-2 and -9 underlie regional decreases in uteroplacental vascularization and feto-placental growth in hypertensive pregnancy Biochem. Pharmacol. 2017 146 101 116 10.1016/j.bcp.2017.09.005 28912068 PMC5705464 · DOI
  70. [71]Laskowska M. Altered maternal serum matrix metalloproteinases MMP-2, MMP-3, MMP-9, and MMP-13 in severe early-and late-onset preeclampsia BioMed Res. Int. 2017 2017 1 9 10.1155/2017/6432426 28798935 PMC5536132 · DOI
  71. [72]Myers J.E. Merchant S.J. MacLeod M. Mires G.J. Baker P.N. Davidge S.T. MMP-2 levels are elevated in the plasma of women who subsequently develop preeclampsia Hypertens. Pregnancy 2005 24 103 115 10.1081/PRG-200059836 16036395 · DOI
  72. [73]Palei A.C. Sandrim V.C. Cavalli R.D.C. Tanus-Santos J.E. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension Clin. Biochem. 2008 41 875 880 10.1016/j.clinbiochem.2008.04.015 18477480 · DOI
  73. [74]Palei A.C. Sandrim V.C. Amaral L.M. Machado J.S.R. Cavalli R.D.C. Duarte G. Tanus-Santos J.E. Association between matrix metalloproteinase (MMP)-2 polymorphisms and MMP-2 levels in hypertensive disorders of pregnancy Exp. Mol. Pathol. 2012 92 217 221 10.1016/j.yexmp.2012.01.008 22327101 · DOI
  74. [75]Martinez-Fierro M.L. Perez-Favila A. Garza-Veloz I. Espinoza-Juarez M.A. Avila-Carrasco L. Delgado-Enciso I. Ortiz-Castro Y. Cardenas-Vargas E. Cid-Baez M.A. Ramirez-Santoyo R.M. Matrix metalloproteinase multiplex screening identifies increased MMP-2 urine concentrations in women predicted to develop preeclampsia Biomarkers 2018 23 18 24 10.1080/1354750X.2017.1279214 28055277 · DOI
  75. [76]Lavee M. Goldman S. Daniel-Spiegel E. Shalev E. Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia Reprod. Biol. Endocrinol. 2009 23 85 10.1186/1477-7827-7-85 19698156 PMC2733305 · DOI
  76. [77]Narumiya H. Zhang Y. Fernandez-Patron C. Guilbert L.J. Davidge S.T. Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia Hypertens. Pregnancy 2001 20 185 194 10.1081/PRG-100106968 12044329 · DOI
  77. [78]Luizon M.R. Palei A.C.T. Sandrim V.C. Amaral L.M. Machado J.S.R. Lacchini R. Tissue inhibitor of matrix metalloproteinase-1 polymorphism, plasma TIMP-1 levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy Pharmacogenom. J. 2014 14 535 541 10.1038/tpj.2014.26 24913092 · DOI
  78. [79]Tayebjee M. Karalis I. Nadar S. Beevers D.J. MacFadyen R. Lip G.Y.H. Circulating matrix metalloproteinase–9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension AJH 2005 18 325 329 10.1016/j.amjhyper.2004.09.014 15797648 · DOI
  79. [80]Ab Hamid J. Mohtarrudin N. Osman M. Asri A.A. Hassan W.H.W. Aziz R. Matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 and 2 as potential biomarkers for gestational hypertension Singap. Med. J. 2012 53 681 683 23112021
  80. [81]Early pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers the screening for pregnancy endpoints (SCOPE) international cohort study Hypertension 2014 64 644 652 10.1161/HYPERTENSIONAHA.114.03578 25122928 · DOI
  81. [82]Wang Z. Lu S. Liu C. Zhao B. Pei K. Tian L. Ma X. Expressional and epigenetic alterations of placental matrix metalloproteinase 9 in preeclampsia Gynecol. Endocrinol. 2010 26 96 102 10.3109/09513590903184100 19724956 · DOI
  82. [84]Zhang Y. Li P. Guo Y. Liu X. Zhang Y. MMP-9 and TIMP-1 in placenta of hypertensive disorder complicating pregnancy Exp. Ther. Med. 2019 18 637 641 10.3892/etm.2019.7591 31258700 PMC6566117 · DOI

Authors
Nikolov, A., & Popovski, N.
Affiliations
Medical University Pleven (BG)
Corresponding author
Nikolov, Asparuh
ORCID
Venue
Diagnostics
Publisher
MDPI AG
Published
2021-03-09
Volume
11
Issue
3
Pages
480
ISSN
2075-4418 (ISSN-L)
DOI
10.3390/diagnostics11030480
PMC
PMC8001076
OpenAlex
W3135491093
Cited by
141
References
84
Citations by year
2026: 15 · 2025: 43 · 2024: 37 · 2023: 18 · 2022: 22 · 2021: 6
FWCI
3.83
Type
journal article
Language
en
Open access
Licence
Locations
  • Diagnostics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Neurological Complications and Syndromes
Keywords
MMP-2, MMP-9, preeclampsia, hypertensive disorders of pregnancy, collagen degradation, type IV collagen, type I collagen, vascular remodeling, spiral arteries, biomarkers, complicated pregnancy, placentation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review